GameStop Corp (NYSE:GME) shares moved lower after Tuesday’s closing bell as the video game retailer reported a year-over-year drop in sales for the first quarter.
Sales for the period ended May 3 were $732.4 million, down from $881.8 million in the year-ago quarter and missing Street forecasts of about $750 million.
eToro Group Ltd shares fell on Tuesday morning as marketing and growth investments hit its profits during its first quarter as a publicly traded company.
The company's income fell to $60 million from $64 million in the year-ago period, attributed to increased investment in marketing and growth.
Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP).
The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.
Northern Superior Resources Inc. (TSX-V:SUP, OTCQX:NSUPF) has reported new drill results from its ongoing 20,000-meter program at the Philibert gold project in Quebec, which have further extended a recently identified high-grade discovery zone.
The latest intercepts include 21.6 metres grading 4.82 grams per ton (g/t) gold, with a higher-grade section of 7 metres at 11.86 g/t gold, and a separate interval of 22.2 metres at 2.09 g/t gold, including 10 metres at 3.54 g/t gold.
JM Smucker (NYSE:SJM) reported mixed results, including a year-over-year drop in sales, for the fiscal fourth quarter, sending its shares more than 13% lower in early trade on Tuesday.
The food brands company, known for Jif peanut butter, Folgers coffee, Hostess snack cakes and Uncrustables, reported Q4 revenue down 3% year-over-year at $2.14 billion, below Street estimates of $2.19 billion.
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company’s investigational HIV drugs.
The FDA’s clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) said on Tuesday it has entered into a distribution agreement with US-based Phospholutions to bring RhizoSorb phosphorus efficiency technology to the Canadian market.
Under the agreement, MustGrow will market and sell RhizoSorb through its sales and distribution division, NexusBioAg.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) rose 9% after the neuro-imaging specialist confirmed its involvement in the first FDA-approved blood test for Alzheimer’s disease diagnosis.
The UK-listed company provided imaging analysis for Fujirebio Diagnostics’ Lumipulse test, which received US regulatory clearance in May.
Filtronic PLC (LSE:FTC) shares jumped 9% on Tuesday after the company announced its largest-ever contract, a $32.5 million (£24 million) order from SpaceX.
The deal, for its high-performance E-band Cerus 32 Solid State Power Amplifier, will be substantially delivered during the 2026 financial year.
Shares in Novo Nordisk (NYSE:NVO), maker of fat-busting jabs such as Ozempic, jumped 3% after the emergence of an activist investor on its share register.
Parvus Asset Management is building a stake in the Danish drug giant, according to the Financial Times, amid investor unease over the company’s position in the competitive weight-loss drug market.